🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Essen
Clinical trial register · Germany

Clinical Trials in Essen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca57 Novartis Pharmaceuticals50 Eli Lilly and Company30 Amgen27 University Hospital, Essen27
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Essen

760 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation
NCT05717192Emphysema or Chronic Obstructive Pulmonary Disease
IHF GmbH - Institut für Herzinfarktforschung
Not applicable
224
Berlin, Bonn, Essen, Halle, Heidelberg, Hemer, Immenhausen, Langen
2024-04-24
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Paraplatin·Taxol·Keytruda
Janssen Research & Development, LLC
Phase 1/2
287
Essen, Leipzig, Stuttgart
2024-04-22
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Bayreuth, Berlin, Bochum, Dresden, Düsseldorf, Essen, Giessen, Hamburg
2024-04-16
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
DrugsLiposomal doxorubicin·Xeloda·Abraxane·Taxol
Merck Sharp & Dohme LLC
Phase 3
1,200
Erlangen, München, Potsdam, Georgsmarienhütte, Düsseldorf, Essen, Saarbrücken, Gera
2024-04-14
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Datopotamab deruxtecan·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Berlin, Bonn, Cologne, Düsseldorf, Essen, Freiburg im Breisgau, Gauting, Georgsmarienhütte
2024-04-11
Recruiting
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
NCT05904106Acute Myeloid Leukemia
DrugsGemtuzumab Ozogamicin·Azacitidine·Venetoclax
Technische Universität Dresden
Phase 2
146
Essen, Aachen, Augsburg, Chemnitz, Cologne, Dresden, Erlangen, Frankfurt am Main
2024-04-07
Active, closed
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
NCT06004661Metastatic Castration-Resistant Prostate Cancer (mCRPC)
DrugsIlluccix·Lu-PSMA
Novartis Pharmaceuticals
Phase 2
23
Essen, München
2024-04-04
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
375
Munich, München, Rosenheim, Hanover, Frankfurt, Essen, Mainz, Leipzig
2024-04-03
Recruiting
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
NCT06274515Breast Cancer
Hoffmann-La Roche
Phase 4
320
Cologne, Essen, Karlsruhe, Mannheim, Ulm
2024-04-02
Not yet open
Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)
NCT05587621ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol
Jena University Hospital
Not applicable
300
Jena, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Homburg
2024-04-01
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
579
Aachen, Berlin, Erlangen, Essen, Greifswald, Hanover, Mainz, München
2024-03-29
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
2,554
Aachen, Amberg, Bad Oeynhausen, Berlin, Bochum, Dresden, Essen, Falkensee
2024-03-29
Active, closed
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201Multiple Sclerosis, Myasthenia Gravis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Essen, Magdeburg, Düsseldorf, Erlangen, München
2024-03-28
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
DrugDostarlimab
GlaxoSmithKline
Phase 3
864
Augsburg, Berlin, Erlangen, Essen, Giessen, Hamburg, Neuruppin, Straubing
2024-03-21
Recruiting
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
NCT06205121Pulmonary Sarcoidosis
Molecure S.A.
Phase 2
96
Essen, Freiburg im Breisgau, Mainz-GE
2024-03-21
Recruiting
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781Low Grade Serous Ovarian Cancer
DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole
Verastem, Inc.
Phase 3
270
Frankfurt am Main, Berlin, Dresden, Essen, Hamburg, Mannheim, Ulm
2024-03-18
Recruiting
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
NCT05904119First Progression of Glioblastoma
DrugLomustine
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
411
Bochum, Cologne, Erlangen, Essen, Heidelberg, Leipzig, Munich, Regensburg
2024-03-15
Recruiting
Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection
NCT06377462VEXAS Syndrome
Technische Universität Dresden
Observational
500
Aachen, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen, Hamburg, Jena
2024-03-13
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
DrugsPiflufolastat·Lu-PSMA
Novartis Pharmaceuticals
Phase 3
450
Munich, Cologne, Aachen, Augsburg, Berlin, Essen, Münster, Rostock
2024-03-12
Recruiting
Randomized Comparison of Skeletonized Versus Pedicled Left Internal Thoracic Artery
NCT05931783Coronary Artery Disease
Medical University Innsbruck
Not applicable
1,350
Essen, Freiburg im Breisgau, Giessen, Jena
2024-03-12
Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381Aortic Stenosis
DrugPelacarsen
Novartis Pharmaceuticals
Phase 2
502
Frankfurt am Main, Kaiserslautern, Dresden, Leipzig, Ahaus, Berlin, Bonn, Essen
2024-03-07
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Aachen, Bad Friedrichshall, Bad Homburg, Berlin, Bielefeld, Cologne, Dresden, Essen
2024-03-05
Recruiting
PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
NCT06320223Prostate Cancer, PET/CT, Survivorship, PSMA
University Hospital, Essen
Observational
10,000
Essen
2024-03-05
Recruiting
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05935215Atypical Hemolytic Uremic Syndrome
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
50
Essen, Kiel
2024-02-28
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Dresden, Essen, Hamburg, Mannheim, Ulm
2024-02-27
Recruiting
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
NCT06035120Emphysema, Pulmonary, Emphysema or COPD
Pulmonx Corporation
Not applicable
200
Essen, Halle, Hamburg, Heidelberg, Hemer
2024-02-22
Recruiting
PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
NCT06247163Small Cell Lung Carcinoma
University Hospital, Essen
Observational
30
Essen
2024-02-22
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Essen, Göttingen, Würzburg
2024-02-20
Recruiting
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
NCT05933057Duchenne Muscular Dystrophy
DrugHydroxyurea
Italfarmaco
Phase 3
138
Berlin, Essen, Freiburg im Breisgau, Hamburg
2024-02-19
Active, closed
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140Carcinoma, Non-Small-Cell Lung
DrugsClobetasol·Minocycline·Chlorhexidine·Clindamycin
Janssen Research & Development, LLC
Phase 2
305
Aachen, Essen, Giessen, Heidelberg, Kassel, Kiel
2024-02-16
Recruiting
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
NCT06078553Congenital Myasthenic Syndrome
argenx
Observational
100
Berlin, Bochum, Essen
2024-02-13
Active, closed
Registry Study on Prescription, Patient Pathways, Therapy Efficacy and Usage of Mandibular Advancement Devices in Obstructive Sleep Apnea - PATT-OSA Registry
NCT03924817Obstructive Sleep Apnea
ResMed
Observational
500
Blaubeuren Abbey, Essen, Berlin, Regensburg
2024-02-01
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
122
Dresden, Essen, München
2024-02-01
Active, closed
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
NCT06150820Pompe Disease (Late-onset)
Astellas Gene Therapies
Not applicable
119
Bonn, Essen, Höchheim, Münster
2024-02-01
Recruiting
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169Glioblastoma, Recurrent Glioblastoma, GBM
DrugsTemodal·Lomustine·Temozolomide·Carboplatin
CarThera
Phase 3
560
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2024-01-29
Recruiting
Adaptive Radiotherapy in Head and Neck Tumor Patients
NCT06216171Head and Neck Neoplasms, Head and Neck Cancer, Adaptive Radiotherapy, Optimization
University Hospital, Essen
Not applicable
30
Essen
2024-01-25
Recruiting
The Pancreatic Enzymes After Gastrectomy Trial
NCT06058442Gastrectomy
University of Leipzig
Phase 3
188
Borna, Cottbus, Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Jena, Leipzig
2024-01-24
Active, closed
Early Genetic Identification of Obesity
NCT06239064Obesity, Childhood, Hyperphagia, Retinopathy, Syndactyly
Rolfs Consulting und Verwaltungs-GmbH (RCV)
Observational
1,000
Aachen, Augsburg, Bad Krozingen, Bielefeld, Bonn, Bückeburg, Cologne, Essen
2024-01-24
Active, closed
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596Metastatic Urothelial Cancer
DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin
BicycleTx Limited
Phase 2
375
Essen
2024-01-24
Active, closed
Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment
NCT05533242Glioblastom WHO Grade 4
University Hospital Muenster
Phase 1
10
Cologne, Essen, Münster, Würzburg
2024-01-22
By invitation
Quality of Life in Patients With Hemorrhagic Telangiectasia
NCT06261333Hereditary Hemorrhagic Telangiectasia
University Hospital, Essen
Observational
250
Essen
2024-01-22
Recruiting
Adaptive Radiotherapy in Patients With Gynecological Tumors
NCT06230549Gynecological Tumor, Adaptive Radiotherapy, Radiation, Curative Treatment
University Hospital, Essen
Not applicable
30
Essen
2024-01-15
Active, closed
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
NCT06246513Limb-girdle Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
17
Essen
2024-01-15
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Berlin, Cologne, Essen, Giessen, Hamburg, Hanover, Heidelberg, Homburg
2024-01-11
Recruiting
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
NCT05949125Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
AvenCell Europe GmbH
Phase 1
37
Ulm, Munich, Würzburg, Marburg, Dresden, Berlin, Cologne, Essen
2024-01-03
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Berlin, Cologne, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hamburg
2023-12-29
Recruiting
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma
DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Rituximab
Bristol-Myers Squibb
Phase 1/2
460
Münster, Homburg, Leipzig, Berlin, Essen
2023-12-29
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
DrugsOdronextamab·Lenalidomide·Rituximab
Regeneron Pharmaceuticals
Phase 3
580
Mutlangen, Stuttgart, Munich, Frankfurt am Main, Essen, Mainz, Halle, Kiel
2023-12-28
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Bielefeld, Bochum, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Heidelberg, Jena
2023-12-27
Recruiting
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
NCT05280314Melanoma, Squamous Cell Carcinoma of Head and Neck
DrugsIO102-IO103·Pembrolizumab KEYTRUDA
IO Biotech
Phase 2
60
Essen, Heidelberg
2023-12-21
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
DrugsMomelotinib·Ruxolitinib
Janssen Research & Development, LLC
Phase 1
300
Aachen, Berlin, Essen, Hanover, Heidelberg, Regensburg
2023-12-20
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugVolrustomig
AstraZeneca
Phase 3
1,145
Berlin, Erlangen, Essen, Freiburg im Breisgau, Greifswald, Hamburg, Hanover, Leipzig
2023-12-14
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)
DrugsOdronextamab·Prednisone/Prednisolone·Cytoxan·Adriamycin
Regeneron Pharmaceuticals
Phase 3
904
Stuttgart, Mutlangen, Frankfurt am Main, Essen, Mainz, Homburg, Dresden, Berlin
2023-12-13
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugNexiguran ziclumeran
Intellia Therapeutics
Phase 3
1,200
Berlin, Essen, Heidelberg, Würzburg
2023-12-13
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Bielefeld, Bochum, Böblingen, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Giessen
2023-12-13
Active, closed
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105GIST
DrugsRipretinib·Sunitinib
Deciphera Pharmaceuticals, LLC
Phase 3
54
Berlin, Essen, Heidelberg, Leipzig
2023-12-13
Recruiting
LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
NCT05714930Systemic Lupus Erythematosus
Heinrich-Heine University, Duesseldorf
Not applicable
606
Freiburg im Breisgau, Heidelberg, Erlangen, Munich, Frankfurt am Main, Hanover, Düsseldorf, Essen
2023-12-12
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Bamberg, Cologne, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Heidelberg, Homburg/Saar
2023-12-11
Active, closed
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
DrugBel-sar
Aura Biosciences
Phase 3
108
Berlin, Cologne, Essen, Hamburg, Lübeck, München, Tübingen
2023-12-06
Active, closed
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT05689671Non-Small Cell Lung Cancer Metastatic
DrugsAbraxane·Tecentriq·Atezolizumab·Nab-paclitaxel
Nikolaj Frost MD
Phase 4
136
Amberg, Augsburg, Bad Homburg, Berlin, Bielefeld, Cologne, Dresden, Essen
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
DrugsAbraxane·Adriamycin·Taxol·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
710
Heilbronn, Mannheim, Ravensburg, Tübingen, Munich, Essen, Dresden, Berlin
2023-12-06
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
DrugsElranatamab·Pomalidomide·Dexamethasone
AstraZeneca
Phase 1/2
226
Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Lübeck, Nuremberg, Tübingen, Würzburg
2023-12-05
Active, closed
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
NCT05993234HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
DrugTrastuzumab deruxtecan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
257
Aschaffenburg, Berlin, Cologne, Essen, Göppingen, Hamburg, Hanover, München
2023-12-05
Active, closed
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
NCT06205706Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
DrugPembrolizumab
BioInvent International AB
Phase 1/2
35
Essen
2023-12-04
Recruiting
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
NCT06408441Epithelioid Hemangioendothelioma, Sarcoma,Soft Tissue
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Observational
100
Essen, München
2023-12-01
Active, closed
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
NCT06128564Duchenne Muscular Dystrophy
Hoffmann-La Roche
Phase 2
13
Essen
2023-11-29
Active, closed
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073Multifocal Motor Neuropathy
argenx
Observational
413
Essen, Giessen, Hanover, Potsdam, Würzburg
2023-11-29
Active, closed
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06173531Hyperphagia in Prader-Willi Syndrome
DrugCarbetocin
ACADIA Pharmaceuticals Inc.
Phase 3
170
Augsburg, Essen
2023-11-27
Recruiting
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Alcyone Therapeutics, Inc
Not applicable
90
Essen
2023-11-27
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
Düsseldorf, Essen, Georgsmarienhütte, Hamburg, Hanover, Heidelberg, Heilbronn, Leipzig
2023-11-23
Active, closed
The PEERLESS II Study
NCT06055920Pulmonary Embolism
Inari Medical
Not applicable
1,200
Augsburg, Bad Krozingen, Berlin, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2023-11-17
Recruiting
Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors
NCT06214611Head and Neck Cancer, Adaptive Radiotherapy, Radiation, Optimized Treatment
University Hospital, Essen
Not applicable
50
Essen
2023-11-15
Recruiting
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
NCT05658640Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsTrametinib·Cytarabine·Dexamethasone·Cyclophosphamide
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2023-11-14
Active, closed
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420Neoplasms, Head and Neck
DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab
GlaxoSmithKline
Phase 2
316
Frankfurt am Main, Essen, Aachen, Berlin, Giessen, Hamburg, Regensburg, Ulm
2023-11-14
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsDatopotamab deruxtecan·Epirubicin·Xeloda·Olaparib
AstraZeneca
Phase 3
1,902
Augsburg, Berlin, Dessau, Dresden, Erlangen, Essen, Esslingen am Neckar, Frankfurt am Main
2023-11-14
Active, closed
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease
NCT06075706Steroid-refractory Acute Graft-versus-host Disease
DrugMC0518
medac GmbH
Phase 2
49
Aachen, Essen, Frankfurt, Freiburg im Breisgau, Giessen, Hanover, Jena, Leipzig
2023-11-13
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
556
Freiburg, Göttingen, Essen, Chemnitz, Dresden, Hamburg
2023-11-12
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Yervoy·Paraplatin·Opdivo
AstraZeneca
Phase 3
863
Berlin, Bochum, Cologne, Essen, Gauting, Georgsmarienhütte, Großhansdorf, Hamburg
2023-11-09
Recruiting
[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
NCT06132737CNS Lymphoma
Pentixapharm AG
Phase 1/2
15
Munich, Essen
2023-11-07
Recruiting
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
NCT05566769Neuromyelitis Optica
Ad scientiam
Not applicable
103
Dresden, Essen, Munich
2023-11-03
Active, closed
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725Spasticity as Sequela of Stroke
Ipsen
Observational
1,057
Altenburg, Berlin, Dresden, Düsseldorf, Essen, Kiel, Lübeck, Mainz
2023-11-01
Active, closed
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332Metastatic Uveal Melanoma
DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy
IDEAYA Biosciences
Phase 2/3
420
Heidelberg, Cologne, Essen, Dresden, Berlin
2023-10-31
Recruiting
Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)
NCT05762211Transplant Complication
MaaT Pharma
Phase 2
387
Augsburg, Berlin, Bonn, Essen, Frankfurt, Hombourg, Kiel, Leipzig
2023-10-31
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease
DrugTreprostinil
United Therapeutics
Phase 3
698
Rosenheim, Hanover, Bad Berka, Coswig, Essen, Immenhausen, Löwenstein, München
2023-10-30
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Freiburg I. Breisgau, Wangen I. Allgaeu, Munich, Münnerstadt, Immenhausen, Stralsund, Essen, Cologne
2023-10-25
Recruiting
GENERATE - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications
NCT05867927GYN Disorders
Intuitive Surgical
Observational
1,250
Hamburg, Wiesbaden, Berlin, Bochum, Coburg, Cologne, Essen, Frankfurt am Main
2023-10-25
Active, closed
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326Adenocarcinoma, Pancreatic Ductal
DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab
Genentech, Inc.
Phase 2
260
Berlin, Bochum, Cologne, Dresden, Essen, Frankfurt, Hamburg, Heidelberg
2023-10-18
Active, closed
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806Multiple Myeloma
DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan
Celgene
Phase 3
79
Heidelberg, Ulm, Nuremberg, Cologne, Leipzig, Dresden, Essen, Hamburg
2023-10-16
Recruiting
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
NCT06357754Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
DrugsIdecabtagene vicleucel·Lisocabtagene maraleucel
Bristol-Myers Squibb
Observational
50
Essen
2023-10-06
Recruiting
European Newborn Study: Early Markers for a Better LifE
NCT07189494Cerebral Palsy
dr. M.J.N.L. Benders
Observational
1,000
Essen
2023-10-06
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Aachen, Berlin, Cologne, Darmstadt, Deggendorf, Dessau, Düsseldorf, Essen
2023-10-05
Recruiting
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment
NCT06033274Tricuspid Regurgitation
Montefiore Medical Center
Observational
800
Munich, Frankfurt am Main, Essen, Lübeck, Bad Oeynhausen, Cologne, Hamburg
2023-10-05
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
106
Munich, Würzburg, Dresden, Jena, Berlin, Essen, Hamburg, Hanover
2023-10-02
By invitation
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
NCT05967351Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
400
Essen
2023-09-27
Recruiting
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
NCT06094101Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma
University Hospital Tuebingen
Phase 1/2
30
Essen, Frankfurt am Main, Freiburg im Breisgau, Tübingen
2023-09-19
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Berlin, Brandenburg an der Havel, Chemnitz, Cologne, Düsseldorf, Erlangen, Essen, Frankfurt
2023-09-18
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Freiburg I. Breisgau, Munich, Münnerstadt, Hamburg, Immenhausen, Marburg, Essen, Cologne
2023-09-14
Active, closed
Avacostar - (PASS)
NCT05897684ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma
Observational
507
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Göttingen, Hamburg, Hanover
2023-09-11
Recruiting
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
NCT05722938Community-acquired Pneumonia
Biotest
Phase 3
590
Freiburg im Breisgau, Hanover, Essen, Berlin, Hamburg
2023-09-09
Active, closed
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 2
268
Berlin, Essen, Frankfurt, Großhansdorf, Hanover, Immenhausen, Jena, Konstanz
2023-09-08
Rows per page Showing 301–400 of 760
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/essen?page=4

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 760 of those studies with a site in Essen.

How many clinical trials are recruiting in Essen?

375 of the 760 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 15 have not yet opened recruitment, 361 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.